Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early palliative care and quality of life of advanced cancer patients-a multicenter randomized clinical trial.
Franciosi V, Maglietta G, Degli Esposti C, Caruso G, Cavanna L, Bertè R, Bacchini G, Bocchi L, Piva E, Monfredo M, Scafuri V, Di Cesare P, Melotti B, Sequino M, Rimanti A, Binovi C, Ghisoni F, Caminiti C. Franciosi V, et al. Among authors: rimanti a. Ann Palliat Med. 2019 Sep;8(4):381-389. doi: 10.21037/apm.2019.02.07. Epub 2019 Mar 14. Ann Palliat Med. 2019. PMID: 30943735 Free article. Clinical Trial.
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V. Dieci MV, et al. Among authors: rimanti a. Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007. Ann Oncol. 2019. PMID: 30657852 Free PMC article. Clinical Trial.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF. Dieci MV, et al. Among authors: rimanti a. BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z. BMC Med. 2019. PMID: 31747948 Free PMC article. Clinical Trial.
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.
Guarneri V, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Nanni O, Piacentini F, Orvieto E, Griguolo G, Curtarello M, Urso L, Paré L, Chic N, D'Amico R, Prat A, Conte P. Guarneri V, et al. Among authors: rimanti a. Clin Cancer Res. 2020 Nov 15;26(22):5843-5851. doi: 10.1158/1078-0432.CCR-20-1731. Epub 2020 Aug 25. Clin Cancer Res. 2020. PMID: 32843527 Clinical Trial.
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
Musolino A, Falcini F, Sikokis A, Boggiani D, Rimanti A, Pellegrino B, Silini EM, Campanini N, Barbieri E, Zamagni C, Degli Esposti R, Cortesi L, Bisagni G, Cavanna L, Frassoldati A, Sgargi P, Michiara M. Musolino A, et al. Among authors: rimanti a. Eur J Cancer. 2018 Jan;88:10-20. doi: 10.1016/j.ejca.2017.10.024. Epub 2017 Nov 23. Eur J Cancer. 2018. PMID: 29175735
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. Conte P, et al. Among authors: rimanti a. Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414. Ann Oncol. 2018. PMID: 30219886 Free article. Clinical Trial.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Among authors: rimanti a. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study.
La Verde N, Collovà E, Blasi L, Pinotti G, Palumbo R, Bonotto M, Garrone O, Brunello A, Rimanti A, Bareggi C, Zaniboni A, Frassoldati A, Foglietta J, Berardi R, Moretti A, Farina G, Porcu L, Barni S. La Verde N, et al. Among authors: rimanti a. Clin Breast Cancer. 2021 Oct;21(5):e489-e496. doi: 10.1016/j.clbc.2020.11.001. Epub 2020 Nov 9. Clin Breast Cancer. 2021. PMID: 33342749 Free article.
16 results